---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-001012"
form_type: "8-K"
ticker: "SBEV"
cik: "0001553788"
company_name: "SPLASH BEVERAGE GROUP, INC."
filed_at: "2026-08-04T20:30:34+00:00"
generated_at: "2026-08-04T20:32:18.254545+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Splash Beverage enters development collaboration with Lupvindol for veterinary drug from CannEpil

## Summary
- Lupvindol to lead FDA INAD and conditional approval for CannEpil-based veterinary product in companion-animal oncology and pain.
- Milestone payments total up to $1.11M plus 4% royalty on net sales (or equity election) upon conditional approval or earlier licensing.
- Splash provides milestone funding and commercial support; Lupvindol handles development and regulatory activities.
- Initial term 5 years, auto-renew; Splash can terminate for convenience with 90 days notice and wind-down fee equal to next milestone.
- Collaboration follows July 2026 exclusive license from Argent Biopharma (RGT) for CannEpil; royalty to RGT is 10% of net revenue for veterinary use.

## SEC filing metadata
- accession: 0001731122-26-001012
- form_type: 8-K
- ticker: SBEV
- cik: 0001553788
- company_name: SPLASH BEVERAGE GROUP, INC.
- filed_at: 2026-08-04T20:30:34+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553788/000173112226001012/0001731122-26-001012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553788/000173112226001012/e7825_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-001012
- JSON: https://secwatch.observer/filing/0001731122-26-001012.json
- Plain text: https://secwatch.observer/filing/0001731122-26-001012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.